Get started
Work

766. Immunotherapy for Her2-Positive Medulloblastoma: Regression of Experimental Tumors by Transfer of Her2-Redirected T Cells In Vivo

Year: 2006
Type: article
Abstract: Background: The long-term objective of this project is to develop an innovative HER2-targeted immunotherapeutic approach for medulloblastoma. HER2 is expressed in 40% of medulloblastomas and at present less than one third of patients with HER2-positive tumors are cured by conventional therapies. The aim of this study was to determine if T cells grafted with a HER2-specific chimeric antigen receptor (CAR) recognize and kill HER2-positive medulloblastomas.
DOI: 10.1016/j.ymthe.2006.08.851
Authors: Nabil M. Ahmed, Maheshika K. Ratnayake, Barbara Savoldo, Laszlo Perlaky, Gianpietro Dotti, Winfried Wels, Meenakshi B. Bhattacharjee, H. David Shine, Cliona M. Rooney, Helen E. Heslop, Stephen Gottschalk
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W1995283721
FWCI:
Cites:
Cited by:
Related to: 10